|
|
Article: Novel gp41 crystal structure licensed from Cornell Research Foundation.
- Article from:
- Pharma Business Week
- Article date:
- November 10, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 NOV 10 - (NewsRx.com & NewsRx.net) -- Locus Pharmaceuticals, Inc., a privately held pharmaceutical company focused on developing small-molecule therapeutics, has licensed from Cornell Research Foundation a proprietary crystal structure of a novel helical domain of gp41.
In combination with its existing gp41 program, Locus plans to apply its proprietary, fragment-based, computational technology to this structure to identify small-molecule inhibitors of HIV, the AIDS virus.
HIV fusion and viral infectivity is dependent upon the protein gp41; thus, blocking this protein activity may represent an important new strategy to developing effective HIV ...